



**PR** 

## **Austrianova Officially Opens New Facilities in Singapore**

Singapore, 30<sup>th</sup> January 2015

Austrianova announced the opening of their new company facilities at Synapse, within Biopolis, a world-class biomedical sciences hub where key research institutes and organisations are located. The Company occupies lab and office space within one self contained unit that has been purpose-built. The Company will continue to perform R&D as well as translational research using it's proprietary cell encapsulation technologies Cell-in-a-Box® and Bac-in-a-Box® at it's new location and the Austrianova headquarters are housed in the same facility. Good Manufacturing Practice (GMP) activities, including the production of biomedical cell products for clinical use, will be carried out at Thailand Science Park in Bangkok. An open house event for guests, including Kenneth Waggoner, CEO of PharmaCyte Biotech Inc., Lim Chuan Poh (Chairman of A-Star), Volker R. Ammann (Head of the Austrian Embassy in Singapore) and Michael A Png (British High Commission) to visit the new Synapse facility was held in the afternoon of January 29<sup>th</sup> 2015.

Brian Salmons, CEO of Austrianova, said "We are pleased to move to the new and larger facilities which have been custom designed to suit our needs at such a prestigious location. The new headquarters will allow us to expand our activities in Singapore".

Dr. John Dangerfield, COO of Austrianova, stated "The move from our former location at the Biopreneur lab in Centros to our new base in Synapse means that we are still located at the heart of the internationally renowned Biopolis, among leading private and public research institutes, incubator research units, translational and clinical researchers and medical technology research".





## About Austrianova:

Austrianova, part of the SG Austria Group, is a biotech company with a global footprint and headquarters in Singapore. Austrianova utilizes a novel and proprietary technology for the encapsulation of living mammalian (Cell-in-a-Box®) and bacterial (Bac-in-a-Box®) cells. Cell-in-a-Box® protects the encapsulated cells from rejection by the immune system, allows cells to be easily transported, stored and implanted at specific sites in patients. The technology, which has been proven safe and efficacious in clinical trials carried out in Europe, allows companies to develop any kind of cells as a one-for-all living pharmaceutical. Bac-in-a-Box® is a similar protective device adapted for encapsulation of probiotic bacteria where it has human food and animal feed applications due to its ability for extending storage under lyophilized conditions and protection in stomach acid.